Direct-acting Antiviral Drug Market by Product Type, Therapeutic Area, Route of Administration, End User, Distribution Channel

List of Tables

The Direct-acting Antiviral Drug Market is projected to grow by USD 34.92 billion at a CAGR of 14.10% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 13.87 billion
Estimated Year [2026]	USD 15.79 billion
Forecast Year [2032]	USD 34.92 billion
CAGR (%)	14.10%

Direct-acting antiviral drugs are reshaping viral disease management by targeting specific steps in viral replication rather than relying mainly on broad immune modulation. In hepatitis C virus care, modern DAA regimens have become the benchmark for precision antiviral therapy, with the World Health Organization reporting cure rates above 95% when patients receive appropriate treatment.

Market momentum is supported by a clear public health mandate. WHO estimates that about 50 million people were living with chronic hepatitis C infection in 2022, with approximately 1 million new infections occurring that year. This creates sustained demand for affordable oral regimens, simplified diagnostics, treatment decentralization, and procurement models that expand access beyond specialist centers.

Transformative Shifts in the DAA Landscape

The most important shift in the direct-acting antiviral drug landscape is the move from complex interferon-based therapy to short-course, all-oral, pan-genotypic regimens. This has reduced treatment duration, improved tolerability, and enabled broader use in primary care, correctional health, harm-reduction settings, and national elimination programs.

Competition is also shifting from clinical efficacy alone to access, adherence, and system-level execution. As patents expire and licensed generic supply expands in many low- and middle-income markets, manufacturers and public health buyers are increasingly focused on price sustainability, diagnostic linkage, resistance monitoring, and real-world treatment completion.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the DAA value chain through patient finding, clinical decision support, pharmacovigilance, and supply planning. AI-enabled risk stratification can help health systems identify undiagnosed hepatitis C among people with historical injection drug use, abnormal liver enzymes, dialysis exposure, incarceration history, or birth-cohort risk.

The cumulative impact is operational rather than speculative. AI can shorten the gap between screening and treatment initiation, forecast demand for national procurement, detect safety signals from real-world data, and support adherence interventions. However, industry leaders must pair AI deployment with validated datasets, privacy safeguards, explainable models, and clinical oversight to avoid bias in underserved populations.

Key Regional Insights for DAA Adoption

Asia-Pacific represents a high-priority region because of large patient pools, expanding generic availability, and government-backed hepatitis elimination initiatives. China, India, Japan, Australia, and South Korea are advancing screening and treatment pathways at different speeds, with India playing a central role in affordable active pharmaceutical ingredient and generic formulation supply. WHO's Western Pacific and South-East Asia regional hepatitis strategies continue to emphasize diagnosis expansion, treatment scale-up, and integration of viral hepatitis services into primary care.

North America remains a high-value market driven by established reimbursement, advanced diagnostics, and strong specialist networks, although treatment gaps persist among uninsured populations, people who inject drugs, and incarcerated individuals. Latin America is improving access through public procurement and regional health programs, with Brazil and Mexico serving as important demand centers where national treatment guidelines and public-sector purchasing shape DAA availability.

Europe benefits from structured elimination strategies, centralized health systems, and mature clinical guidelines, but progress varies by country and by linkage-to-care capacity. The Middle East, particularly GCC markets, shows rising investment in specialty medicines and national screening supported by broader health transformation programs. Africa has the greatest access challenge, where disease burden, limited diagnostics, and financing constraints make low-cost regimens, simplified testing, and decentralized care essential to improve treatment coverage.

Key Group Insights Across Strategic Markets

ASEAN markets are characterized by diverse reimbursement systems, growing diagnostic capacity, and significant need for affordable pan-genotypic therapy, particularly where out-of-pocket costs and limited specialist coverage affect linkage to care. The GCC is positioned as a premium access cluster, supported by national health transformation programs, hospital modernization, and the ability to fund broad screening initiatives for viral hepatitis and related liver disease.

The European Union provides one of the most structured policy environments for DAA access, with strong regulatory oversight, established health technology assessment pathways, and cross-country evidence generation. BRICS countries combine high patient volumes with expanding domestic pharmaceutical capabilities, making them central to large-scale treatment access and generic competition. G7 countries continue to shape clinical standards, pharmacovigilance expectations, and premium innovation pathways, while NATO member states overlap with many high-income procurement systems that prioritize resilient medicine supply chains, continuity of essential therapies, and health security preparedness.

Key Country Insights for Commercial Strategy

The United States remains a commercially important DAA market, supported by advanced diagnostics and broad clinical expertise, but affordability, payer authorization, and underserved populations continue to shape treatment uptake. Canada emphasizes public health access and provincial reimbursement, while Mexico and Brazil are key Latin American markets where public procurement, national hepatitis programs, and public hospital networks influence demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature treatment pathways supported by specialist care networks, national guidelines, and established reimbursement processes, while Russia represents a large patient opportunity with access shaped by domestic policy, registration requirements, and procurement dynamics. China combines large disease prevalence with expanding local innovation and volume-based purchasing, while India is a major access market and global generic supplier. Japan, Australia, and South Korea are advanced markets with strong screening infrastructure, high clinical standards, and ongoing elimination priorities aligned with international viral hepatitis targets.

Actionable Recommendations for Industry Leaders

Industry leaders should align DAA strategy with the full care cascade: screening, confirmatory testing, treatment initiation, adherence, and post-treatment follow-up. The strongest opportunities will come from simplifying access in primary care, integrating treatment into harm-reduction programs, correctional health, and community clinics, and partnering with governments on hepatitis elimination targets.

Organizations should also strengthen real-world evidence programs, support affordable pricing models, and build supply resilience for active ingredients and finished-dose products. Digital patient navigation, AI-supported case finding, and collaboration with laboratories can reduce loss to follow-up and improve measurable cure outcomes. Leaders should prioritize ethical data use, pharmacovigilance readiness, and locally adapted access models to improve both clinical impact and long-term market relevance.

Research Methodology

This executive summary is developed using secondary research from authoritative public health, regulatory, clinical, and industry sources, including global disease burden updates, treatment guidelines, product approvals, procurement trends, and peer-reviewed evidence on DAA effectiveness.

The analysis triangulates epidemiology, access dynamics, regional policy signals, competitive behavior, and technology adoption to identify market direction. Insights are validated through consistency checks across public datasets, clinical guidance, regulatory information, and market-access evidence, with emphasis on verifiable trends rather than unsupported forecasts, market sizing, or market share estimates.

Conclusion

The direct-acting antiviral drug market is defined by a rare combination of high clinical efficacy, clear public health demand, and expanding access potential. With cure rates above 95% for appropriate hepatitis C treatment, DAAs remain one of the most impactful therapeutic classes in infectious disease and a critical tool for achieving viral hepatitis elimination objectives.

Future leadership will depend on more than product performance. Organizations that combine affordable access, evidence generation, AI-enabled patient identification, reliable supply, and region-specific partnerships will be best positioned to support elimination goals while sustaining long-term relevance in direct-acting antiviral therapy.

Product Code: MRR-032A67D91452

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Direct-acting Antiviral Drug Market, by Product Type

7.1. Branded Drugs
7.2. Generic Drugs

8. Direct-acting Antiviral Drug Market, by Therapeutic Area

8.1. Hepatitis C Virus (HCV) Antivirals
- 8.1.1. NS5A Inhibitors
- 8.1.2. NS5B Polymerase Inhibitors
- 8.1.3. NS3/4A Protease Inhibitors
8.2. Hepatitis B Virus (HBV) Antivirals
- 8.2.1. Capsid Assembly Modulators
- 8.2.2. Entry Inhibitors
- 8.2.3. RNA Interference (RNAi)-Based Agents
8.3. HIV Direct-Acting Antivirals
- 8.3.1. Protease Inhibitors
- 8.3.2. Integrase Strand Transfer Inhibitors (INSTIs)
- 8.3.3. Reverse Transcriptase Inhibitors
8.4. Influenza & Respiratory Virus DAAs

9. Direct-acting Antiviral Drug Market, by Route of Administration

9.1. Oral Direct-Acting Antivirals
9.2. Injectable DAAs
9.3. Intravenous DAAs
9.4. Long-Acting Depot Formulations

10. Direct-acting Antiviral Drug Market, by End User

10.1. Home Healthcare
10.2. Hospitals
10.3. Specialty Clinics

11. Direct-acting Antiviral Drug Market, by Distribution Channel

11.1. Online
11.2. Offline

12. Direct-acting Antiviral Drug Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Direct-acting Antiviral Drug Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Direct-acting Antiviral Drug Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Concentration Analysis, 2025
- 15.1.1. Concentration Ratio (CR)
- 15.1.2. Herfindahl Hirschman Index (HHI)
15.2. Recent Developments & Impact Analysis, 2025
15.3. Product Portfolio Analysis, 2025
15.4. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AbbVie Inc.
16.2. Beximco Pharmaceuticals Ltd.
16.3. Bristol-Myers Squibb Company
16.4. Cipla Limited
16.5. Dr. Reddy's Laboratories Ltd.
16.6. Gilead Sciences, Inc.
16.7. GlaxoSmithKline plc
16.8. Hetero Labs Limited
16.9. Johnson & Johnson
16.10. Lupin Limited
16.11. Merck & Co., Inc.
16.12. Novartis AG
16.13. Pfizer Inc.
16.14. Regeneron Pharmaceuticals, Inc.
16.15. Roche Holding AG
16.16. Sun Pharmaceutical Industries Limited
16.17. Vertex Pharmaceuticals Incorporated